Heres how BPC-157 could enhance each of these aspects: Accelerated Tissue Repair One of the standout benefits of BPC-157 is its ability to accelerate tissue repair
The SELECT trial, comprising 17,604 patients, was conducted at 804 sites across 41 countries, focused on patients aged 45 or older with a BMI of at least 27 kg/m and preexisting CVD but no history of diabetes
The other added the requirement of a procedure, specifically an intravitreal injection with an anti-VEGF medication, within 30 days of the neovascular AMD diagnosis to increase the likelihood of identifying active disease
A key part of this will be the SURMOUNT-Real UK study, which will look at the effects of tirzepatide in a primary care setting on weight loss, prevention of obesity-related conditions, health-related quality of life, and changes in employment status and sick day absences, compared with usual care over 5 years